Pyxis Oncology (PYXS) Net Cash Flow (2020 - 2025)
Pyxis Oncology (PYXS) posted quarterly Net Cash Flow of $6.5 million for Q4 2025, down 12.32% year-over-year from $7.4 million in Q4 2024, and up 458.49% quarter-over-quarter from -$1.8 million in Q3 2025.
Pyxis Oncology (PYXS) Net Cash Flow (2020 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has reported Net Cash Flow for 6 consecutive years, with $6.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Net Cash Flow fell 12.32% year-over-year to $6.5 million; the TTM figure through Dec 2025 stood at -$4.0 million (down 140.62% YoY), while the FY2025 annual figure was -$4.1 million, down 141.3% from the prior year.
- Net Cash Flow advanced to $6.5 million in Q4 2025 per PYXS's latest filing, from -$1.8 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $142.7 million in Q4 2021 and bottomed at -$126.2 million in Q1 2023.
- Historically, Net Cash Flow has averaged $132400.0 across 5 years, with a median of -$5.9 million in 2023.
- Annual changes were most pronounced in 2021 — Net Cash Flow surged 4608.24% — and 2022, when it slumped 1417.86%.
- Pyxis Oncology's Net Cash Flow stood at $142.7 million in 2021, then slumped by 113.48% to -$19.2 million in 2022, then jumped by 73.75% to -$5.1 million in 2023, then surged by 246.84% to $7.4 million in 2024, then decreased by 12.32% to $6.5 million in 2025.
- Business Quant data shows PYXS's Net Cash Flow at $6.5 million in Q4 2025, -$1.8 million in Q3 2025, and -$2.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Pyxis Oncology | 198.37 Mn | 165.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.50 Mn |
| Dec 31, 2025 | 6.50 Mn |
| Sep 30, 2025 | -1.81 Mn |
| Sep 30, 2025 | -1.81 Mn |
| Jun 30, 2025 | -1.96 Mn |
| Jun 30, 2025 | -1.96 Mn |
| Mar 31, 2025 | -6.71 Mn |
| Mar 31, 2025 | -6.71 Mn |
| Dec 31, 2024 | 7.42 Mn |
| Dec 31, 2024 | 7.42 Mn |
| Sep 30, 2024 | -13.02 Mn |
| Sep 30, 2024 | -13.02 Mn |
| Jun 30, 2024 | -2.89 Mn |
| Jun 30, 2024 | -2.89 Mn |
| Mar 31, 2024 | 18.30 Mn |
| Mar 31, 2024 | 18.30 Mn |
| Dec 31, 2023 | -5.05 Mn |
| Dec 31, 2023 | -5.05 Mn |
| Sep 30, 2023 | -11.18 Mn |
| Sep 30, 2023 | -11.18 Mn |